65,437 trials
Vulvovaginitis · Yeast Infection · Yeast Infection Vaginal
Primary: Clinical Outcome Assessed at Test of Cure Visit — 13; 12; 24; 12 Participants
Lymphocytic Leukemia, Chronic
Primary: Progression-Free Survival (PFS) as Assessed Using Kaplan-Meier Estimate — 50.6; 33.7 months
Social Anxiety Disorder
Primary: Social Phobia and Anxiety Inventory (SPAI) - Social Phobia Subscale — 131.66; 130.17; 75.47; 103.9 units on a scale
Atopic Dermatitis
Primary: Change From Baseline in Total Lesion Symptom Score (TLSS) — 6.3; 6.6; -1.9; -1.9 units on a scale — p=0.636
Prevention & Control
Primary: The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death — 379; 448; 496 Participants — p=0.00004
Nicotine Dependence
Primary: Carbon Monoxide Levels — 9.2 parts per million
Submental Fullness
Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) — 13.2; 8.7; 20.0; 5.2 percentage of participants
Depression
Primary: Recovery Time — 3.0; 6.7 minutes
Lung Cancer
Primary: Boost Dose Toxicity — 5 Participants
Cystitis, Interstitial · Ulcer
Primary: Change From Baseline in the Daily Average Bladder Pain Numeric Rating Scale (NRS) — -1.6; -2.7; -2.5 score on a scale — p=0.142
Disease, Pulmonary
Primary: Number of Participants With Frailty Phenotype at Baseline and 6 Months — 24; 15 Participants — p=0.62
Skin Diseases, Infectious
Primary: Clinical Response at Test of Cure (TOC) — 86.2; 80.0; 0.0; 6.9 Percentage of participants
Contraceptive Usage
Primary: Number of Participants With Contraceptive Implant Continuation at Six Months Postpartum — 15; 7 Participants
Safety · Tolerability · Pharmacokinetics
Primary: Safety and Tolerability of AZD9567 by Assessing the Number of Participants With Adverse Events — 0; 0; 1; 0 Participants
Cytomegalovirus Disease
Primary: Number of Patients With Late CMV Disease — 0; 0 Participants